RegenXBio Secures Up to $250 Million by Monetizing Royalties from Zolgensma and Two Gene Therapies
RegenXBio has secured a strategic royalty monetization agreement with HealthCare Royalty (HCRx) worth up to $250 million.
The deal includes a $150 million upfront payment, immediately extending RegenXBio’s cash runway into early 2027, with an additional $50 million due by April 2027 upon achieving Zolgensma sales milestones, and another possible $50 million upon mutual agreement.
HealthCare Royalty obtains rights to anticipated royalty and milestone payments from Zolgensma (marketed by Novartis for spinal muscular atrophy), as well as upcoming gene therapies RGX-121 (pending FDA approval for Hunter syndrome) and RGX-111 (being developed for Hurler syndrome).
RegenXBio will use this non-dilutive capital to accelerate commercialization efforts for its pipeline and continue advancing its gene therapy portfolio.
HCRx also receives warrants to purchase up to 268,096 shares of RegenXBio at a premium, and will be paid quarterly interest from the royalty and milestone revenue.
RegenXBio retains rights to other funding sources, including potential Priority Review Voucher proceeds for RGX-121 and milestone payments from additional partners such as AbbVie and Nippon Shinyaku.
This is RegenXBio’s second major royalty monetization deal with HCRx, following a $200 million agreement in 2020.